COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma-Reference-Cited by-同舟云学术

COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma

Published:2023-09 Issue:30 Volume:19 Page:2017-2027
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

van Akkooi Alexander CJ¹^ORCID,Hauschild Axel²^ORCID,Long Georgina V³^ORCID,Mandala Mario⁴^ORCID,Kicinski Michal⁵^ORCID,Govaerts Anne-Sophie⁵,Klauck Isabelle⁶,Ouali Monia⁷,Lorigan Paul C⁸^ORCID,Eggermont Alexander MM⁹¹⁰^ORCID

Affiliation:

1. Melanoma Institute Australia, the University of Sydney & Royal Prince Alfred Hospital, 40 Rocklands Road Wollstonecraft, Sydney 2065, NSW, Australia

2. Department of Dermatology, University Hospital (UKSH), Arnold-Heller-Straße 3, 24105, Kiel, Germany

3. Melanoma Institute Australia, University of Sydney, & Mater & Royal North Shore Hospitals, 40 Rocklands Road Wollstonecraft, Sydney 2065, NSW, Australia

4. University of Perugia, Ospedale Santa Maria della Misericordia, Piazzale Giorgio Menghini, 3, 06129, Perugia, Italy

5. EORTC Headquarters, Avenue Emmanuel Mounier 83/11, 1200, Brussels, Belgium

6. Pierre Fabre, Medical & Patient/Consumer Division, 33 avenue Emile Zola, 92100, Boulogne-Billancourt, France

7. Pierre Fabre, Medical & Patient/Consumer Division, Langlade, France

8. Christie NHS Foundation Trust, Wilmslow Road Manchester M20 4BX, UK

9. University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands

10. Comprehensive Cancer Center Munich, Technical University Munich & Ludwig Maximiliaan University, Marchioninistraße 15, 81377 Munich, Germany

Abstract

Stage IIB/IIC melanoma has a high risk of recurrence after surgical resection. While, for decades, surgery was the only option for high-risk stage II disease in most countries, adjuvant therapies now exist. Anti-programmed cell death protein 1 (PD-1) antibodies significantly improve recurrence-free survival versus placebo in patients with fully resected stage IIB/IIC melanoma. Combined BRAF MEK inhibitor therapy showed benefits in high-risk stage III and advanced disease; however, its role in patients with fully resected stage BRAF-mutated IIB/IIC melanoma is still unknown. Here we describe the rationale and design of the ongoing randomized, placebo-controlled COLUMBUS-AD trial, the first study of a BRAF-MEK inhibitor combination therapy (encorafenib + binimetinib) in patients with BRAF V600-mutated stage IIB/IIC melanoma.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2023-0414

Reference44 articles.

1. Epidemiology of Melanoma

2. International Agency for Research on Cancer. Cancer over time (2021). https://gco.iarc.fr/overtime (Accessed 23 December 2021).

3. Considering adjuvant therapy for stage II melanoma

4. Epidemiology and survival outcomes in stages II and III cutaneous melanoma: a systematic review

5. Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of Melanoma

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dataset: Impact of β-Galactosylceramidase Overexpression on the Protein Profile of Braf(V600E) Mutated Melanoma Cells;Data;2023-11-24

2. CRISPR-Cas System Is an Effective Tool for Identifying Drug Combinations That Provide Synergistic Therapeutic Potential in Cancers;Cells;2023-11-09